Agios Pharmaceuticals Inc
AGIO
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
134.7% downsideOvervalued by 134.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.75 Billion |
|---|---|
| Enterprise Value | $1.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.12 |
| Beta | 0.58 |
| Outstanding Shares | 58,782,241 |
Return
| Return on Equity | -38.10% |
|---|---|
| Return on Assets | -35.66% |
| Return on Invested Capital | -42.23% |
Valuation & Multiples
| P/E Ratio | -4.09 |
|---|---|
| PEG | -37.18 |
| Price to Sales | 27.68 |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | 25.29 |
| Enterprise Value to EBIT | -3.51 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1077▼ 20.93% |
|---|---|
| Total Calls | 3,650,500▼ 20.32% |
| Total Puts | 393,300▼ 72.92% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 108.74%▲ 3.37% |
|---|---|
| Total Invested | $2.12B▲ 27.09% |
| Investors Holding | 247▼ 9.00% |
ESG Score
No data
About Agios Pharmaceuticals Inc
536 employees
CEO: Jacqualyn Fouse Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...
Relevant Senate Committees
The most powerful economic committee, controlling taxation, trade, and entitlement spending (Medicare/Medicaid). Directly impacts corporate valuations through tax policy and significantly affects pharmaceutical revenue through drug pricing and reimbursement.
Allocates discretionary federal spending, including funding for NIH (research vital to pharma) and potentially VA/Medicare (drug purchasing). Directly impacts the financial landscape for R&D and sales.
Directly regulates the FDA (drug approval), NIH (research funding), and influences labor laws. This committee has primary oversight of the core regulatory and funding environment for pharmaceutical companies.
Oversees DOJ, antitrust laws, and intellectual property. IP protection (patents) is critical for pharmaceutical companies like Agios, and antitrust actions can impact market competition and M&A.
Investigates issues affecting older Americans, including drug pricing. While lacking legislative authority, its hearings create significant 'headline risk' and political pressure for pharmaceutical companies regarding drug costs.